Reference

Intravenous dolasetron for the prevention of postoperative nausea and vomiting after outpatient laparoscopic gynecologic surgery

Intravenous dolasetron for the prevention of postoperative nausea and vomiting after outpatient laparoscopic gynecologic surgery. Graczyk, Sarena G.; McKenzie, Ray; Kallar, Surindar; Hickok, Charles B.; Melson, Timothy; Morrill, Bruce; Hahne, William F.In this study，115956-12-2 is also used.; Brown, Robert A. (Anesthesiologists Columbia, PA, USA). Anesthesia & Analgesia (Baltimore), 84(2), 325-330 (English) 1997 Williams & Wilkins. CODEN: AACRAT. ISSN: 0003-2999. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The newer 5-hydroxytryptamine type 3 (5-HT3) antagonists are sometimes considered for routine prophylaxis of postoperative nausea and vomiting (PONV) in high-risk patients. This multicenter, randomized, double-blind, placebo-controlled study compared the efficacy and safety of three single i.v. doses of dolasetron mesylate salt (12.5, 25, or 50 mg) for the prevention of PONV in 635 females undergoing outpatient laparoscopic gynecol. surgery. Antiemetic efficacy was evaluated over a 24-h postoperative period by recording the no. and timing of emetic episodes; effects on nausea were evaluated by a visual analog scale (VAS). The proportion of complete responders (no emetic episodes and no escape medication in 24 h) was significantly higher with each dolasetron mesylate dose (>50%) for each dose; (P ￡ 0.0003) than with placebo (30.6%). Fewer patients given dolasetron required or requested escape antiemetic medication compared with placebo (P < 0.0003). Dolasetron-treated patients had significantly (P < 0.0357) lower median postdose max. nausea VAS scores compared with placebo-treated patients. Patient satisfaction with dolasetron was high and, overall, was significantly (P = 0.0131) greater than that with placebo. Dolasetron was an effective and well tolerated preventive treatment for PONV resulting from laparoscopic gynecol. surgery. .

Simultaneous measurement of dolasetron and its major metabolite, MDL 74,156, in human plasma and urine

Simultaneous measurement of dolasetron and its major metabolite, MDL 74,156, in human plasma and urine. Huebert, N.Some chemicals with cas registry numbers like 115956-12-2 and 127951-99-9 are also used. D.; Schwartz, J.-J.; Zeidler, L.; Schwach, V.; Haegele, K. D. (Marion Merrell Dow, 16 rue d'Ankara, 67080, Strasbourg, Fr.). Journal of Chromatography, B: Biomedical Applications, 685(2), 291-297 (English) 1996 Elsevier. CODEN: JCBBEP. ISSN: 0378-4347. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) A selective and sensitive anal. method for the simultaneous measurement of dolasetron (I) and its major metabolite, MDL 74,156 (II), in human plasma and urine samples has been developed using a structural analog, MDL 101,858, as internal std. (I.S.). The compds. were extd. from plasma and urine using solvent extn. after the addn. of the I.S. Chromatog. sepn. was carried out on a reversed-phase HPLC column and detection and quantification was by fluorescence with excitation and emission wavelengths of 285 and 345 nm, resp. Linear responses were obtained over concn. ranges of 5 to 1000 pmol/mL for plasma samples and 20 to 1000 pmol/mL for urine samples with correlation coeffs. for the calibration curves exceeding 0.999 in all cases. Intra-day and inter-day reproducibility yielded limits of quantification of 10 pmol/mL for I and 5 pmol/mL for II in plasma and 50 pmol/mL for I and II in urine. The method has been applied to the simultaneous anal. of both compds. in plasma and urine samples coming from clin. pharmacokinetic studies. .